Get the Stockscreener App
2.50
9.19%
-0.2531
Evoke Pharma Inc stock is traded at $2.50, with a volume of 19,798.
It is down -9.19% in the last 24 hours and down -33.51% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$2.7531
Open:
$2.68
24h Volume:
19,798
Relative Volume:
0.98
Market Cap:
$4.25M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.2267
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
-15.09%
1M Performance:
-33.51%
6M Performance:
-49.60%
1Y Performance:
-65.85%
1-Day Range:
$2.46
$2.7074
1-Week Range:
$2.46
$3.0077
52-Week Range:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
2.50 | 4.25M | 8.62M | -6.15M | -5.32M | -11.03 |
|
RGC
Regencell Bioscience Holdings Ltd
|
23.70 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.34 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.49 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.97 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance
Gastroparesis Treatment Market Booming Worldwide with - openPR.com
Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com
Geriatric Medicines Market Expands Globally with Aging - openPR.com
Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com
Global Geriatric Medicines Market Generated Opportunities, - openPR.com
Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World
Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus
Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times
Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire
Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World
FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - Yahoo Finance
Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech
Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal
Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World
Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):